CAS 928672-86-0 Puritas ≥99.0% (HPLC) API

Description:

CAS: 928672-86-0

Aspectus: pulveris albi

Puritas: ≥99.0% (HPLC)

Inhibitor in curatione aegroti cum Type 2 diabete Mellito

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Chemical Properties:

CAS Number	928672-86-0
CATTUS Number	RF-API22
Stock Status	In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae	C24H27FO6S
M. Pondus	462.53
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba pulveris
Lepidium sativum	HPLC/NMR
Solubilitas	Solubile in Methanol;Solubile in Ethanol, Acetonitrile;Leviter solutum in aqua
Puritas / Analysis Methodus	≥99.0% (HPLC)
Individual Impurity	≤0.10%
Totalis immunditias	≤0.50%
RELICTUM Solvents
Methanol	≤3000ppm
Ethanol	≤5000ppm
Acetonitrile	≤400ppm
Dichloromethane	≤600ppm
Ethyl Acetate	≤5000ppm
THF	≤720ppm
Toluene	≤890ppm
Test Standard	Pharmacopoeia Sinica (CP);Enterprise Standard
Consuetudinem	Active Pharmaceutical Ingredient (API);SGLT-2 inhibitores Typus 2 Diabete

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore

commoda:

FAQ:

Applicatio:

Medicamentum est de gliflozin genere vel subtypo 2 sodium-glucosi inhibitores onerariorum (SGLT2) adhibitorum ad tractationem diabetarum specierum 2 diabetarum.Mitsubishi Tanabe Pharma amplificatum est et venales sub licentia a Janssen, Johnson & Johnson divisione facta est.Auctor est reabsorptionis glucosi saltem 90% in renibus.Clausus portator glucose sanguinem per urinam exstingui facit.Mense Martio 2013, primus SGLT2 inhibitor probandus in Civitatibus Foederatis Americae factus est.TO commodum, hoc medicamento adiuvat aegros ad sanguinem saccharorum minuendum sine augendo verisimilitudinem pondus lucrandi, dum sanum, libratum victu sequitur et exercitatio regularis sumpta.Praeterea amplam habet prospectum ob eius significativas antiobesitatis effectus et paucos eventus hypoglycemicos.